{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:59:54Z","timestamp":1786132794850,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","award":["73313"],"award-info":[{"award-number":["73313"]}],"id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["DP2-DK124891-01"],"award-info":[{"award-number":["DP2-DK124891-01"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","award":["2015A051179"],"award-info":[{"award-number":["2015A051179"]}],"id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2020,9]]},"abstract":"\n Significance Statement<\/jats:title>\n \n APOL1<\/jats:italic>\n alleles G1 and G2 are associated with high incidence and rapid progression of CKD in blacks of West African ancestry. The mechanism of\n APOL1<\/jats:italic>\n cytotoxicity is poorly understood, partly because cell-based models express variable amounts of APOL1 and yield contradictory results. Experiments using a stable human embryonic kidney cell line (HEK293) demonstrate that expression of G1 or G2 at relevant levels causes dose-dependent cytotoxicity, but the wild-type reference allele G0 does not. G0 does not reduce cytotoxicity of G1 or G2\n APOL1<\/jats:italic>\n . The mutant alleles therefore introduce a dominant toxic gain-of-function. Dose-dependent G1 or G2 cytotoxicity could explain incomplete penetrance of\n APOL1<\/jats:italic>\n nephropathy. Reducing expression of G1 or G2 could represent a therapeutic strategy for\n APOL1<\/jats:italic>\n nephropathy.\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n \n Two coding renal risk variants (RRVs) of the\n APOL1<\/jats:italic>\n gene (G1 and G2) are associated with large increases in CKD rates among populations of recent African descent, but the underlying molecular mechanisms are unknown. Mammalian cell culture models are widely used to study cytotoxicity of RRVs, but results have been contradictory. It remains unclear whether cytotoxicity is RRV-dependent or driven solely by variant-independent overexpression. It is also unknown whether expression of the reference\n APOL1<\/jats:italic>\n allele, the wild-type G0, could prevent cytotoxicity of RRVs.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n We generated tetracycline-inducible\n APOL1<\/jats:italic>\n expression in human embryonic kidney HEK293 cells and examined the effects of increased expression of\n APOL1<\/jats:italic>\n (G0, G1, G2, G0G0, G0G1, or G0G2) on known cytotoxicity phenotypes, including reduced viability, increased swelling, potassium loss, aberrant protein phosphorylation, and dysregulated energy metabolism. Furthermore, whole-genome transcriptome analysis examined deregulated canonical pathways.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n At moderate expression, RRVs but not G0 caused cytotoxicity in a dose-dependent manner that coexpression of G0 did not reduce. RRVs also have dominant effects on canonical pathways relevant for the cellular stress response.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n In HEK293 cells, RRVs exhibit a dominant toxic gain-of-function phenotype that worsens with increasing expression. These observations suggest that high steady-state levels of RRVs may underlie cellular injury in\n APOL1<\/jats:italic>\n nephropathy, and that interventions that reduce RRV expression in kidney compartments may mitigate\n APOL1<\/jats:italic>\n nephropathy.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.2020010079","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T18:02:44Z","timestamp":1594922564000},"page":"2083-2096","source":"Crossref","is-referenced-by-count":71,"title":["Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function"],"prefix":"10.1681","volume":"31","author":[{"given":"Somenath","family":"Datta","sequence":"first","affiliation":[{"name":"Division of Nephrology and Duke Molecular Physiology Institute, Duke University, Durham, North Carolina"},{"name":"Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Kataria","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah","family":"Moore","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Petitpas","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-2608","authenticated-orcid":false,"given":"Nathan","family":"Zahler","sequence":"additional","affiliation":[{"name":"Icagen Inc, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin R.","family":"Pollak","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Division of Nephrology, Beth Israel Deaconess Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Opeyemi A.","family":"Olabisi","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Duke Molecular Physiology Institute, Duke University, Durham, North Carolina"},{"name":"Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"B1-20231016","doi-asserted-by":"crossref","first-page":"e1002150","DOI":"10.1371\/journal.pgen.1002150","article-title":"Differential effects of MYH9 and APOL1 risk variants on FRMD3 association with diabetic ESRD in african Americans","volume":"7","author":"Freedman","year":"2011","journal-title":"PLoS Genet"},{"key":"B2-20231016","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"B3-20231016","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00439-010-0861-0","article-title":"Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene","volume":"128","author":"Tzur","year":"2010","journal-title":"Hum Genet"},{"key":"B4-20231016","doi-asserted-by":"crossref","first-page":"114","DOI":"10.5414\/CNP86S116","article-title":"From man to fish: What can Zebrafish tell us about ApoL1 nephropathy?","volume":"86","author":"Olabisi","year":"2016","journal-title":"Clin Nephrol"},{"key":"B5-20231016","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nm.4287","article-title":"Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice","volume":"23","author":"Beckerman","year":"2017","journal-title":"Nat Med"},{"key":"B6-20231016","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1073\/pnas.1522913113","article-title":"APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases","volume":"113","author":"Olabisi","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7-20231016","doi-asserted-by":"crossref","first-page":"BSR20171713","DOI":"10.1042\/BSR20171713","article-title":"APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress","volume":"38","author":"Wen","year":"2018","journal-title":"Biosci Rep"},{"key":"B8-20231016","doi-asserted-by":"crossref","first-page":"F326","DOI":"10.1152\/ajprenal.00647.2013","article-title":"APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability","volume":"307","author":"Lan","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"B9-20231016","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1681\/ASN.2016050567","article-title":"APOL1 renal-risk variants induce mitochondrial dysfunction","volume":"28","author":"Ma","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B10-20231016","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1073\/pnas.1820414116","article-title":"Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity","volume":"116","author":"Chun","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B11-20231016","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1073\/pnas.1716113115","article-title":"UBD modifies APOL1-induced kidney disease risk","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12-20231016","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1681\/ASN.2016121322","article-title":"ApoL1 overexpression drives variant-independent cytotoxicity","volume":"29","author":"O\u2019Toole","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B13-20231016","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1681\/ASN.2010121234","article-title":"Genetic variation in APOL1 associates with younger age at hemodialysis initiation","volume":"22","author":"Kanji","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B14-20231016","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/ndt\/gfr796","article-title":"APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease","volume":"27","author":"Tzur","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B15-20231016","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1681\/ASN.2014050469","article-title":"APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans","volume":"26","author":"Kasembeli","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B16-20231016","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1681\/ASN.2011040388","article-title":"APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy","volume":"22","author":"Kopp","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B17-20231016","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nmeth.1314","article-title":"SUnSET, a nonradioactive method to monitor protein synthesis","volume":"6","author":"Schmidt","year":"2009","journal-title":"Nat Methods"},{"key":"B18-20231016","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1681\/ASN.2016111220","article-title":"Intracellular APOL1 risk variants cause cytotoxicity accompanied by energy depletion","volume":"28","author":"Granado","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B19-20231016","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/febs.15133","article-title":"Alterations in plasma membrane ion channel structures stimulate NLRP3 inflammasomes activation in APOL1 risk milieu","volume":"287","author":"Jha","year":"2019","journal-title":"FEBS J"},{"key":"B20-20231016","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s42003-018-0188-2","article-title":"APOL1 risk allele RNA contributes to renal toxicity by activating protein kinase R","volume":"1","author":"Okamoto","year":"2018","journal-title":"Commun Biol"},{"key":"B21-20231016","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1681\/ASN.2015050487","article-title":"Combined effects of GSTM1 null allele and APOL1 renal risk alleles in CKD progression in the african American study of kidney disease and hypertension trial","volume":"27","author":"Bodonyi-Kovacs","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B22-20231016","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI20402","article-title":"Induction of B7-1 in podocytes is associated with nephrotic syndrome","volume":"113","author":"Reiser","year":"2004","journal-title":"J Clin Invest"},{"key":"B23-20231016","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.kint.2016.02.032","article-title":"APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease","volume":"90","author":"Ma","year":"2016","journal-title":"Kidney Int"},{"key":"B24-20231016","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1681\/ASN.2019020114","article-title":"APOL1 kidney risk variants induce cell death via mitochondrial translocation and opening of the mitochondrial permeability transition pore","volume":"30","author":"Shah","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B25-20231016","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1097-2765(00)00108-8","article-title":"Regulated translation initiation controls stress-induced gene expression in mammalian cells","volume":"6","author":"Harding","year":"2000","journal-title":"Mol Cell"},{"key":"B26-20231016","article-title":"Effect of a single apolipoprotein L1 gene nephropathy variant on the risk of advanced lupus nephritis in Brazilians [published online ahead of print Nov 15, 2019]","author":"Vajgel","journal-title":"J Rheumatol"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2020010079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:24:12Z","timestamp":1786130652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2020010079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2020010079","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}